Select to expand quote
remery said..Flying Dutchman said..
1)B
2)C
3)B
4)IL-7(There's two 'C's)
5)A
6)A
Nice work. Can you elaborate on how it is that there are "several cell types expressing IL-7 receptors including not only T cells but also ILC, T cells, M1/M2 monocytes, DCs, eosinophils, and neutrophils. When IL-7 is administered through subcutaneous or intramuscular route, various skin-related side effects can occur due to the response of skin-resident ILC or T cells to IL-7. Changing the administration route to intravenous injection can help address these issues. Alternatively, developing an immunocytokine with targeting moiety to T cell such as anti-CD3, -CD4, or -CD8 that selectively activates IL-7 in T cells through 'cis-acting' could be another viable option, reducing the activation in non-target cells."?
Thanks ChatGPT 3.5

IL-7 Receptors: Interleukin-7 (IL-7) is a cytokine involved in regulating the immune system. It acts by binding to IL-7 receptors present on the surface of various immune cells. These receptors are not exclusive to T cells; they are also expressed on other immune cell types such as innate lymphoid cells (ILCs), monocytes (including M1/M2 subsets), dendritic cells (DCs), eosinophils, and neutrophils.
Administration Routes and Side Effects: When IL-7 is administered through subcutaneous or intramuscular routes, it can lead to skin-related side effects. This is likely due to the response of immune cells residing in the skin, such as ILCs or T cells, to the IL-7 stimulus.
Intravenous Injection: Changing the administration route to intravenous injection can potentially mitigate these skin-related side effects. This is because intravenous delivery allows for more direct and uniform distribution of IL-7 throughout the body, potentially reducing the localized response in the skin.
Immunocytokine Approach: Another approach involves developing an immunocytokine, which is a fusion protein combining a cytokine (in this case, IL-7) with an antibody fragment that specifically targets certain immune cells. In this scenario, the targeting moiety of the immunocytokine would be directed towards T cells, utilizing antibodies against T cell surface markers such as CD3, CD4, or CD8. By selectively activating IL-7 only in T cells through a mechanism known as "cis-acting," the activation of IL-7 in non-target cells could be minimized. This targeted approach aims to enhance the therapeutic effects of IL-7 while reducing potential side effects associated with its non-specific activation in various immune cell types.
In summary, the provided information outlines different strategies to modulate the effects of IL-7 in the immune system, considering its diverse receptor expression and potential side effects upon administration. These strategies include altering the route of administration and developing targeted immunocytokines to selectively activate IL-7 in specific immune cell populations.